OrbusNeich Medical Group Holdings (FRA:Q8T) EBIT : €40.2 Mil (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is OrbusNeich Medical Group Holdings EBIT?

OrbusNeich Medical Group Holdings's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €19.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €40.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. OrbusNeich Medical Group Holdings's annualized ROC % for the quarter that ended in Jun. 2024 was 20.21%. OrbusNeich Medical Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 57.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. OrbusNeich Medical Group Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 27.54%.

OrbusNeich Medical Group Holdings EBIT Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings EBIT Chart

OrbusNeich Medical Group Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

7.12

3.79

21.95

45.63

40.71

OrbusNeich Medical Group Holdings Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EBIT	Get a 7-Day Free Trial					11.48	25.93	19.87	19.89	20.26

Competitive Comparison of OrbusNeich Medical Group Holdings's EBIT

For the Medical Instruments & Supplies subindustry, OrbusNeich Medical Group Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OrbusNeich Medical Group Holdings's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OrbusNeich Medical Group Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OrbusNeich Medical Group Holdings's EV-to-EBIT falls into.

OrbusNeich Medical Group Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €40.2 Mil.

OrbusNeich Medical Group Holdings (FRA:Q8T) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

OrbusNeich Medical Group Holdings's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	31.834 * ( 1 - 11.33% )	/	( (133.447	+	145.895)	/ 2 )
=	28.2272078	/	139.671
=	20.21 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	376.102	-	8.106	-	( 234.549	-	max(0, 32.667	-	319.082	+	234.549	))
=	133.447

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	385.939	-	10.855	-	( 229.189	-	max(0, 33.362	-	323.052	+	229.189	))
=	145.895

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

OrbusNeich Medical Group Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	39.782	/	( ( (16.933 + max(46.144, 0))	+	(23.44 + max(51.155, 0)) )	/	2 )
=	39.782	/	( ( 63.077	+	74.595 )	/	2 )
=	39.782	/	68.836
=	57.79 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(34.815	+	37.988	+	0.40999999999997)	-	(8.106	+	0	+	18.963)
=	46.144

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(33.131	+	45.441	+	0.55200000000002)	-	(10.855	+	0	+	17.114)
=	51.155

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

OrbusNeich Medical Group Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	40.15	/	145.764
	=	27.54 %

OrbusNeich Medical Group Holdings EBIT Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

OrbusNeich Medical Group Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (FRA:Q8T) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

06929:Hong Kong

Address

3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG

Website

https://www.orbusneich.com

OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

OrbusNeich Medical Group Holdings Headlines

No Headlines